Founders Fund V Management’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Founders Fund V Management’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-480,708	Closed	-$284K	–	4
2024 Q4	$284K	Hold	480,708	–	–	16.84%	2
2024 Q3	$379K	Hold	480,708	–	–	66.35%	1
2024 Q2	$610K	Hold	480,708	–	–	72.16%	1
2024 Q1	$668K	Hold	480,708	–	–	61.13%	1
2023 Q4	$764K	Buy	+480,708	New	+$613K	80.75%	1

Founders Fund V Management's CYTH Position: Q1 2025 in Review

Founders Fund V Management sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 480,708 shares — an estimated $284K sold.

Founders Fund V Management first reported a position in CYTH in Q4 2023 and held it in 5 quarters. The position peaked at $764K in Q4 2023. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

Founders Fund V Management reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Founders Fund V Management sold 480,708 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $284K.
Founders Fund V Management first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2023 and held it in 5 quarters.
Founders Fund V Management's Cyclo Therapeutics, Inc. Common Stock position peaked at $764K in Q4 2023.
0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Founders Fund V Management's 13F filing for Q1 2025, filed 15 May 2025.